Could a psychedelic vaccine prevent depression?

A New Vaccine Against Depression? | MYND Life Sciences

While many psychedelics companies are developing treatments for depression, MYND Life Sciences hopes to prevent depression from developing in the first place.

MYND recently signed a licensing agreement with Eyam, a private vaccine developer, to create a vaccine that would prevent neurological disorders including depression. The underlying theory is that depression is essentially neuro-inflammation, and psychedelics may have an anti-inflammatory effect that could prevent the neuro-inflammatory process.

PDF of article

MYND Life Sciences makes progress in treating Alzheimer’s and dementia with psilocybin

MYND Life Sciences Expands Intellectual Portfolio to Target Alzheimer’s disease and related forms of Dementia with Chemical Subclasses of Psilocybin Analogues

You won’t want to forget about this company when choosing your investments. The research team at MYND Life Sciences Inc. (MYND) has been exploring new subclasses of psilocybin that have shown potential to delay or reverse Alzheimer’s disease and other forms of dementia. The preclinical research has shown significant progress, and MYND aims to commence clinical trials to advance the research.

PDF of article